+

WO2001088162A3 - Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations - Google Patents

Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations Download PDF

Info

Publication number
WO2001088162A3
WO2001088162A3 PCT/US2001/014817 US0114817W WO0188162A3 WO 2001088162 A3 WO2001088162 A3 WO 2001088162A3 US 0114817 W US0114817 W US 0114817W WO 0188162 A3 WO0188162 A3 WO 0188162A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
processes
relates
methods
avian species
Prior art date
Application number
PCT/US2001/014817
Other languages
English (en)
Other versions
WO2001088162A2 (fr
Inventor
Lingxun Duan
Original Assignee
Genway Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/573,442 external-priority patent/US6951742B1/en
Application filed by Genway Biotech Inc filed Critical Genway Biotech Inc
Priority to AU2001259631A priority Critical patent/AU2001259631A1/en
Publication of WO2001088162A2 publication Critical patent/WO2001088162A2/fr
Publication of WO2001088162A3 publication Critical patent/WO2001088162A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/20—Heterogeneous data integration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de production d'anticorps polyclonaux et monoclonaux dirigés contre un antigène chez une espèce aviaire, de préférence chez un poulet, au moyen d'une vaccination polynucléotidique. L'invention concerne également des procédés de détermination du profil protéomique d'un ensemble de séquences d'ADN présélectionnées isolées d'un échantillon biologique, de préférence le profil protéomique d'une banque d'ADNc humains. L'invention concerne en outre des procédés d'identification de marqueurs physiologiquement différenciables associés à un échantillon biologique physiologiquement anormal. L'invention concerne finalement des réseaux d'anticorps, des bases de données intégrées destinées à l'identification de gènes et de protéines, des vecteurs d'expression de gènes multi-fonctionnels, ainsi que des procédés de production et d'utilisation de ces réseaux d'anticorps, des bases de données intégrées et des vecteurs d'expression de gènes multi-fonctionnels.
PCT/US2001/014817 2000-05-16 2001-05-07 Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations WO2001088162A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001259631A AU2001259631A1 (en) 2000-05-16 2001-05-07 Methods and vectors for generating antibodies in avian species and uses therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20489900P 2000-05-16 2000-05-16
US09/573,442 2000-05-16
US60/204,899 2000-05-16
US09/573,442 US6951742B1 (en) 1998-11-16 2000-05-16 Methods and vectors for generating antibodies in avian species and uses therefor

Publications (2)

Publication Number Publication Date
WO2001088162A2 WO2001088162A2 (fr) 2001-11-22
WO2001088162A3 true WO2001088162A3 (fr) 2002-09-19

Family

ID=26899888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014817 WO2001088162A2 (fr) 2000-05-16 2001-05-07 Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations

Country Status (2)

Country Link
AU (1) AU2001259631A1 (fr)
WO (1) WO2001088162A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002359913A1 (en) * 2001-12-20 2003-07-09 Agricultural Research Council Semi-synthetic antibody fragment combinatorial library based on avian immunoglobulin genes
CN1818651B (zh) * 2006-03-13 2010-07-21 东北农业大学 兔抗鹅IgY+IgY(△Fc)(H+L)辣根过氧化物酶标记抗体
CN102137928A (zh) * 2008-08-29 2011-07-27 西福根有限公司 克隆禽源抗体的方法
CA2755784C (fr) 2009-03-16 2020-03-24 Pangu Biopharma Limited Compositions et procedes comprenant des variants d'epissage d'histidyl-arnt synthetase presentant des activites biologiques non canoniques
CN102449143B (zh) 2009-03-31 2017-11-14 Atyr医药公司 包含具有非常规生物活性的天冬氨酰‑tRNA合成酶的组合物和方法
JP6066900B2 (ja) 2010-04-26 2017-01-25 エータイアー ファーマ， インコーポレイテッド システイニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6294074B2 (ja) 2010-04-27 2018-03-14 エータイアー ファーマ， インコーポレイテッド イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
US9034320B2 (en) 2010-04-29 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
WO2011135459A2 (fr) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Méthodes et dispositifs permettant de prédire l'efficacité d'un traitement
AU2011248230B2 (en) 2010-05-03 2016-10-06 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
CA2797277C (fr) 2010-05-03 2021-02-23 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps liees a des fragments proteiques d'arginyle-arnt synthetases
CN105820252B (zh) 2010-05-03 2020-07-21 Atyr 医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9062302B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
WO2011143482A2 (fr) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Découverte de compositions inédites de nature thérapeutique, diagnostique et à base d'anticorps contenant des fragments protéiques de phénylalanyl-bêta-arnt synthétases
AU2011256366C1 (en) 2010-05-17 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
JP6046607B2 (ja) 2010-05-27 2016-12-21 エータイアー ファーマ， インコーポレイテッド グルタミニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011261486B2 (en) 2010-06-01 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2836836A1 (fr) 2011-06-01 2012-12-06 Medical Prognosis Institute A/S Procedes et dispositifs pour le pronostic d'une rechute du cancer
CA2864300A1 (fr) 2012-02-16 2013-08-22 Atyr Pharma, Inc. Histidyl-arnt synthetases pour le traitement de maladies auto-immunes et inflammatoires
JP6309019B2 (ja) 2012-11-27 2018-04-11 ポンティフィシア・ウニベルシダッド・カトリカ・デ・チレＰｏｎｔｉｆｉｃｉａ Ｕｎｉｖｅｒｓｉｄａｄ Ｃａｔｏｌｉｃａ ｄｅ Ｃｈｉｌｅ 甲状腺腫瘍を診断するための組成物および方法
US10392667B2 (en) 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2016008048A1 (fr) 2014-07-15 2016-01-21 Ontario Institute For Cancer Research Procédés et dispositifs permettant de prédire l'efficacité d'un traitement à l'anthracycline
GB2579856A (en) * 2018-12-18 2020-07-08 Emergex Vaccines Holding Ltd MHC Class I associated peptides for prevention and treatment of hepatitis B virus infection
WO2021205408A1 (fr) * 2020-04-10 2021-10-14 Igy Immune Technologies And Life Sciences Inc. Immunoglobulines igy ciblant le coronavirus, procédés pour les préparer, et procédés les utilisant
CN117821469B (zh) * 2023-11-22 2024-08-02 扬州大学 一种鸡trim45截短体重组蛋白或其多克隆抗体的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024268A1 (fr) * 1993-04-14 1994-10-27 Arthur Webster Pty. Ltd. Vecteur d'adenovirus de recombinaison avien
WO2000029444A1 (fr) * 1998-11-16 2000-05-25 Genway Biotech, Inc. Generation d'anticorps par vaccination polynucleotidique dans le cas d'une espece aviaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024268A1 (fr) * 1993-04-14 1994-10-27 Arthur Webster Pty. Ltd. Vecteur d'adenovirus de recombinaison avien
WO2000029444A1 (fr) * 1998-11-16 2000-05-25 Genway Biotech, Inc. Generation d'anticorps par vaccination polynucleotidique dans le cas d'une espece aviaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROLLIER CHRISTINE ET AL: "Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection.", JOURNAL OF VIROLOGY, vol. 74, no. 10, May 2000 (2000-05-01), pages 4908 - 4911, XP002192933, ISSN: 0022-538X *
SAKAGUCHI M ET AL: "Protection of chickens from Newcastle disease by vaccination with a linear plasmid DNA expressing the F protein of Newcastle disease virus", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 14, no. 8, 1 June 1996 (1996-06-01), pages 747 - 752, XP004069557, ISSN: 0264-410X *

Also Published As

Publication number Publication date
AU2001259631A1 (en) 2001-11-26
WO2001088162A2 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
WO2001088162A3 (fr) Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations
ITRM930301A1 (it) Procedimento per la preparazione di immunogeni e reagenti diagnostici, e immunogeni e reagenti diagnostici cosi' ottenibili.
EP1616876A3 (fr) Procédé d'identification, d'isolation et de production d'antigènes a un pathogène spécifique
US8241894B2 (en) Method for analyzing proteins
WO2004001381A8 (fr) Cible de surface cellulaire raag10 et famille d'anticorps reconnaissant cette cible
WO2003099999A3 (fr) Production et selection d'une banque de proteines dans de la silice
ATE439380T1 (de) Methoden zur herstellung humaner monoklonaler antikörper
ATE282717T1 (de) Neuartiges verfahren zur identifizierung von klonen mit einer gewünschten biologischen eigenschaft, ausgehend von einer expressionsgenbank
DE602004018388D1 (de) Proteinphosphorylierung bei grosszellig-anaplastischem lymphom
ATE430198T1 (de) Antikörperkonstruktion unter verwendung einer mrl/lpr-maus
BR9915732A (pt) Geração de anticorpos usando-se vacinação de polinucleotìdeo em espécie de ave
Todd et al. The immunogenicity and antigenicity of proteins
EP1405862A3 (fr) Procédé d'identification des peptides antigéniques
EP2287177A3 (fr) Antigènes I + II de Streptococcus agalactiae
WO1999036568A3 (fr) Procede d'identification de fragments de proteine stimulant les lymphocytes t
PH12021550470A1 (en) Improved anti-flt3 antigen binding proteins
WO2004020456A3 (fr) Selection d'anticorps monoclonaux humains therapeutiques dans des bibliotheques specifiques de maladies
WO1999000671A3 (fr) Procede d'identification d'antigenes de proteines cellulaires et de detection de la presence d'anticorps diriges contre des proteines cellulaires specifiques du serum
WO2002033084A3 (fr) Identification de la glycoproteine du groupe sanguin dombrock utilisee en tant qu'element polymorphe de la famile du gene de l'adp/ribosyltransferase
Coligan et al. Production of antipeptide antisera
WO2001085989A3 (fr) Facteurs specifiques aux filaments mycelliens extraits de candida albicans
WO2002000829A3 (fr) Nouveau polypeptide, proteine humaine 16.83 ftsh, et polynucleotide codant ce polypeptide
WO2000034294A3 (fr) Homologue recepteur du facteur de necrose tumorale (trh1)
WO2001059114A3 (fr) Nouveau gene suppresseur de tumeurs p47ing3
Lin-Fa et al. Use of a gene-targeted phage display random epitope library to map an antigenic determinant on the bluetongue virus outer capsid protein VP5

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载